Real-world use, effectiveness, and safety of second-line lurbinectedin monotherapy in small cell lung cancer.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-26 DOI:10.1080/14796694.2025.2499441

Apar Kishor Ganti, Ralph B D'Agostino, Victoria Allan, Patricia Prince, Adina Estrin, Nileesa Gautam, Anne Boccuti, Badri Rengarajan, Wenyan Li, Yanyan Cao, Xiaozhou Fan, Elizabeth M Poole

{"title":"Real-world use, effectiveness, and safety of second-line lurbinectedin monotherapy in small cell lung cancer.","authors":"Apar Kishor Ganti, Ralph B D'Agostino, Victoria Allan, Patricia Prince, Adina Estrin, Nileesa Gautam, Anne Boccuti, Badri Rengarajan, Wenyan Li, Yanyan Cao, Xiaozhou Fan, Elizabeth M Poole","doi":"10.1080/14796694.2025.2499441","DOIUrl":null,"url":null,"abstract":"Aim: Assess real-world outcomes of lurbinectedin and other second-line treatments (OST) in adults with small cell lung cancer that progressed on/after chemotherapy.Patients & methods: US-based electronic medical data from Flatiron Health (01/01/2013-03/31/2022) were used. Baseline characteristics, including chemotherapy-free interval (CTFI), in patients receiving lurbinectedin or OST were balanced using propensity score (PS) overlap weighting.Results: Before PS-weighting, median (95% confidence interval [CI]) real-world progression-free survival (rwPFS) was 2.46 months (2.07-2.73), and real-world response rate (rwRR) was 27.5% (23.1-32.4) in 374 eligible lurbinectedin-treated patients. After PS-weighting, median rwPFS was 2.73 months (2.33-3.32) and 2.53 months (2.23-2.99) in 291 lurbinectedin-treated patients and 261 OST-treated patients, respectively; rwRR was 30.9% and 31.8% (relative risk, 0.97). Lurbinectedin demonstrated numerically improved median rwPFS (3.61 versus 3.02 months) and rwRR (38.7% versus 36.1%) versus OST in patients with CTFI ≥90 days but not in patients with CTFI <90 days (2.00 months both; 20.5% versus 26.1%). Lurbinectedin-treated patients reported less grade ≥3 thrombocytopenia (11.7%) and anemia (6.5%) versus OST (27.2% and 20.3%, respectively); prevalence by CTFI status were similar.Conclusion: Lurbinectedin demonstrated comparable real-world effectiveness with OST with a favorable safety profile; however, these findings are limited by small sample size.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1675-1685"},"PeriodicalIF":3.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2499441","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Assess real-world outcomes of lurbinectedin and other second-line treatments (OST) in adults with small cell lung cancer that progressed on/after chemotherapy.

Patients & methods: US-based electronic medical data from Flatiron Health (01/01/2013-03/31/2022) were used. Baseline characteristics, including chemotherapy-free interval (CTFI), in patients receiving lurbinectedin or OST were balanced using propensity score (PS) overlap weighting.

Results: Before PS-weighting, median (95% confidence interval [CI]) real-world progression-free survival (rwPFS) was 2.46 months (2.07-2.73), and real-world response rate (rwRR) was 27.5% (23.1-32.4) in 374 eligible lurbinectedin-treated patients. After PS-weighting, median rwPFS was 2.73 months (2.33-3.32) and 2.53 months (2.23-2.99) in 291 lurbinectedin-treated patients and 261 OST-treated patients, respectively; rwRR was 30.9% and 31.8% (relative risk, 0.97). Lurbinectedin demonstrated numerically improved median rwPFS (3.61 versus 3.02 months) and rwRR (38.7% versus 36.1%) versus OST in patients with CTFI ≥90 days but not in patients with CTFI <90 days (2.00 months both; 20.5% versus 26.1%). Lurbinectedin-treated patients reported less grade ≥3 thrombocytopenia (11.7%) and anemia (6.5%) versus OST (27.2% and 20.3%, respectively); prevalence by CTFI status were similar.

Conclusion: Lurbinectedin demonstrated comparable real-world effectiveness with OST with a favorable safety profile; however, these findings are limited by small sample size.

查看原文本刊更多论文

鲁比丁二线单药治疗小细胞肺癌的实际应用、有效性和安全性。

目的：评估鲁比丁和其他二线治疗（OST）对化疗后进展的成人小细胞肺癌患者的实际预后。患者和方法：使用美国Flatiron Health的电子医疗数据（2013年1月1日- 2022年3月31日）。基线特征，包括化疗间隔（CTFI），在接受鲁比奈定或OST的患者使用倾向评分（PS）重叠加权进行平衡。结果：在ps加权之前，374名符合条件的鲁比丁治疗患者的真实世界无进展生存期（rwPFS）中位数（95%置信区间[CI]）为2.46个月（2.07-2.73），真实世界缓解率（rwRR）为27.5%（23.1-32.4）。经ps加权后，鲁比丁组291例、ost组261例的中位rwPFS分别为2.73个月（2.33-3.32）和2.53个月（2.23-2.99）；rwRR分别为30.9%和31.8%（相对危险度为0.97）。在CTFI≥90天的患者中，与OST相比，Lurbinectedin在数字上改善了中位rwPFS（3.61个月对3.02个月）和rwRR(38.7%对36.1%)，但在CTFI患者中没有。结论：Lurbinectedin显示出与OST相当的实际有效性，具有良好的安全性；然而，这些发现受到样本量小的限制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.